Chimerix, Inc. (CMRX)

[weedtrader420]

CMRX Should move up where SIGA trades over $10

[weedtrader420]

Big news out smallpox drug

[weedtrader420]

Pump pump pump it up CMRX

[Golden Cross]

CMRX Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement
RDUS acquired for $10/sh cash + $1.00 cvr

[weedtrader420]

Get your monkeypox vaccine CMRX

[weedtrader420]

CMRX$ WOOHOOOOOO

[zeusgodmd]

They also have vaccines for Ebola

[zeusgodmd]

Monkey pox, small pox. They will use our vaccination for this should triple from here

[willlbone]

Lot a bag holders now.

[Pennybuster]

Adding

[ClayTrader]

* * $CMRX Video Chart 01-08-2021 * *

Link to Video - click here to watch the technical chart video

[SmokeSignals]

I THINK WE HAVE A LOW PRICED WINNER!!!! IMO (I HOPE) LOL

[SmokeSignals]

Chimerix to Participate in Upcoming Investor Conferences

DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:

-- H.C. Wainwright 22nd Annual Global Investment Conference: Chimerix will

present a corporate overview on Monday, September 14 at 1:00 p.m. ET and

participate in investor meetings.

-- Cantor Fitzgerald Virtual Healthcare Conference: Management will

participate in investor meetings on Wednesday, September 16.

A live audio webcast of the H.C. Wainwright conference presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

DSTAT is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that, compared to commercially available forms of heparin, may be dosed at higher levels without associated bleeding-related complications. DSTAT is being studied in a Phase 2/3 trial to assess safety and efficacy in adults with acute lung injury with underlying COVID-19. A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been agreed to with the US Food and Drug Administration (FDA) and site activation is expected in early 2021. BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, www.chimerix.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT:

Investor Relations:

Michelle LaSpaluto

919 972-7115

[e-mail]

Will O'Connor

Stern Investor Relations

212-362-1200

[e-mail]

Media:

David Schull

Russo Partners

858-717-2310

[e-mail]

> Dow Jones Newswires

September 10, 2020 08:00 ET (12:00 GMT)

[SmokeSignals]

CMRX LOOKIN RIPE IMO

[ClayTrader]

* * $CMRX Video Chart 04-29-2020 * *

Link to Video - click here to watch the technical chart video

[trendzone]

Andriole Michael T. Chief business officer buys 33,000 shares at $1.42 a share,keep selling clueless fools that are being manipulated by some very corrupted MM's,when insiders add shares usually means they know something big is coming that will move their stock to higher levels.

[ernie44]

don't know how I got into CMRX----maybe because I loved CMKX so much

[ClayTrader]

* * $CMRX Video Chart 02-25-2020 * *

Link to Video - click here to watch the technical chart video

[Gonefishing25]

I think its gonna Go Up QUICKLY!

[willlbone]

Dilution to pay for more clinical trials likely.

[ClayTrader]

* * $CMRX Video Chart 12-03-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $CMRX Video Chart 11-07-19 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $CMRX Video Chart 10-25-2019 * *

Link to Video - click here to watch the technical chart video

[PennyStock Alert]

Well, this held up reasonably well in light of the market wide tax loss dump.

[stockguard]

Big pharma’s billion-dollar bets
As patents lapse and funding on R&D is cut, big pharma is spending big money on risky takeovers to find the next blockbuster drug. In this animated film, Due Diligence's Arash Massoudi explains how Bristol-Myers Squibb’s $90B takeover of Celgene has set the stage for more to come in 2019.
As investors have exerted pressure on big pharma to cut back spending on research and development that can result in expensive disappointments, incumbents have been acquiring smaller competitors to replenish drug pipelines.
Nimble start-ups, in contrast, are not weighed down by legacy businesses and can focus on innovation. Many fail but those that succeed, or even show promise by producing just one drug, instantly become takeover targets.
Underpinning these acquisitions is a gamble. Should a big company buy a start-up that has potential but has not proven its worth? Or wait and miss out on a short cut to high returns and new products?

https://bigdeal.ft.com/videos/big-pharmas-billion-dollar-bets/?utm_source=TW&utm_medium=publishers&utm_content=image_card

[stockguard]

The 6 analysts offering 12-month price forecasts for Catalyst Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 10.00 and a low estimate of 5.50.

[stockguard]

Institutional investors purchased a net $12.300,000 million shares of CPRX during the quarter ended March 2019, and now own 59.81% of the total float, a percentage that is typical for companies in the Pharmaceuticals:

Latest Institutional Activity

3/31/2019 CONSONANCE CAPITAL MANAGEMENT LP Bought 8.5 Million shares of Catalyst Pharmaceuticals

3/31/2019 OPALEYE MANAGEMENT, INC. Bought 1.8 Million shares of Catalyst Pharmaceuticals

3/31/2019 MANGROVE PARTNERS Bought 1.1 Million shares of Catalyst Pharmaceuticals

https://money.cnn.com/quote/shareholders/shareholders.html?symb=CPRX&subView=insider

[ClayTrader]

* * $CMRX Video Chart 05-14-2019 * *

Link to Video - click here to watch the technical chart video

[stocktrademan]

CMRX buy 3.7342



normal chart







log chart

[ernie44]

one word----LACLUSTRE

[ClayTrader]

* * $CMRX Video Chart 04-09-2019 * *

Link to Video - click here to watch the technical chart video

[dirkv]

https://finance.yahoo.com/news/chimerix-announces-management-updates-210000639.html

[ernie44]

wassa matter witt dis dang ting

[ernie44]

expect something ? on wednesday

[Rapture2020]

Expecting big things tomorrow!

[ernie44]

nice move----CMRX

Should be ex-lax

[ernie44]

Lets not rely on the democrats who think the world owes them a living

[ernie44]

alas, the greeks speak a different language so its all greek to me

[ernie44]

GREAT....... we may see over the moon $5 again

[H8ster]

Chimerix to present Phase 1 data for CMX521 at the 31st annual ISAR, The International Conference on Antiviral Research June 11th-June 15th 2018.

Q1 CC

"Details of the discovery and preclinical development of CMX521 will be presented next month at the International Conference on Antiviral Research. Our ongoing Phase 1 studies are designed to evaluate the pharmacokinetics, safety and tolerability of this novel nucleoside. Data from Phase 1 will allow us to choose optimize dosing regimens to take into Phase 2 efficacy studies in 2019."

"In late 2017, we initiated our first time in human study of CMX521, a nucleoside analog identified from our chemical library as a potential treatment and/or prevention for norovirus. We see this as a great commercial opportunity, as there are currently no approved therapies for the treatment of chronic norovirus infection or for use as a prevention strategy to limit the spread of an outbreak."………….

"Norovirus represents a large and costly unmet need. Each year, there are over 700 million cases resulting in 219,000 deaths. There’s also a significant economic toll, as the cost associated with norovirus is over $60 billion a year. And it’s not just a cruise ship virus, as it frequently impacts long-term care facilities and hospitals, causing ward shutdowns and infections among patients and health care providers.

Approaching the different prevention market segments will include looking at a number of important variables depending upon the setting. For example, in a norovirus outbreak, where there’s central area of control, such as in military facilities, hospitals or medical care settings, a protocol for use can be put in place to quickly disseminate an antiviral for preventing the further spread of this highly contagious virus.

We’ve already done exploratory market research with long-term care facilities, who are very interested in the CMX521 product profile, indicating that the product could have utility not only for preventing infection in patients, but also protecting staff."

[H8ster]

Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)

Address Congressional Subcommittee

DURHAM, N.C., June 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey, MD, MPH will deliver remarks before the House Committee on Energy and Commerce Subcommittee on Health at the hearing titled “Examining the Reauthorization of the Pandemic and All-Hazards Preparedness Act” at 10 a.m. ET on Wednesday, June 6 in Washington, D.C.

The purpose of the hearing is to reauthorize certain programs under the Pandemic and All-Hazards Preparedness Act (PAHPA), which originally passed in 2006 and seeks to improve the United States’ public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental or natural. The draft reauthorization legislation would increase funding for the Biomedical Advanced Research and Development Authority (BARDA) and the Project BioShield Special Reserve Fund, a secure funding source for the purchase and stockpile of critical medical countermeasures such as vaccines, therapeutics and diagnostics.

“Unfortunately, the threat of a biological event impacting the United States has never been more real,” said Dr. Berrey. “Our private-public partnerships over the last 15 years, particularly with BARDA, have been critical to the survival and progression of our smallpox program with brincidofovir. We commend the Committee for bipartisan collaboration on the PAHPA reauthorization. Companies like ours rely on the existence of a government market for medical countermeasures to sustain the long-term investment of researching and developing these therapies, which provide a critical bulwark against biological threats.”……………...

[H8ster]

What new FDA designation means for Durham's Chimerix

Durham-based biopharma Chimerix (Nasdaq: CMRX) has banked a new designation from the U.S. Food and Drug Administration.

The FDA granted Chimerix Orphan Drug Designation for its lead drug candidate brincidofovir – known as brinci – for the treatment of smallpox. Benefits of the designation include the likes of development incentives and tax credits.

While members of the Chimerix team were traveling and unavailable for interviews, a company representative said the significance of the designation is two-fold.

“First, it underscores the critical need for the research and development of lifesaving medical countermeasures in the event of a smallpox outbreak, whether naturally occurring or the result of a bioterror event,” the representative noted. “Second, it provides many benefits, including a waiver of the FDA Prescription Drug User Fee Act.”…………………...


FDA designation

[H8ster]

Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox

Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for brincidofovir for the treatment of smallpox.

Chimerix has been working with the Biomedical Advanced Research and Development Authority (BARDA) since 2011 to develop brincidofovir as a medical countermeasure for smallpox, demonstrating improved survival rates following confirmed orthopoxvirus infections in multiple animal models.

“We are very pleased to have received Orphan Drug Designation from the FDA for brincidofovir as a treatment for smallpox,” said M. Michelle Berrey, MD, MPH, President and Chief Executive Officer of Chimerix. “Though declared eradicated in the late 1970s, smallpox, whether natural or synthetic, continues to be a potential global threat in today’s interconnected world. We are committed to completing the development program for brincidofovir as a much-needed treatment option for smallpox, in close collaboration with BARDA and FDA.”

Orphan Drug Designation

[H8ster]

Looking good from here!

[Shaka_Zulu]

Break out to 7.50?

Might enter at 5.25

[ernie44]

snowed in cabin dwellers are taking profits...causing mm to cover

[ernie44]

almost time to get more cheap shares

[ernie44]

CHARTS GALLORE


https://stockcharts.com/c-sc/sc?s=CMRX&p=D&b=5&g=0&i=p29743012051&r=1347046823097

[ernie44]

not worth the gamble right now---see if santa sells at 3.77

[ernie44]

some rookie wants to buy at 1.05, while tousands and tousands hold on